These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31880804)

  • 1. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
    Fournier E; Duployez N; Ducourneau B; Raffoux E; Turlure P; Caillot D; Thomas X; Marceau-Renaut A; Chantepie S; Malfuson JV; Lemasle E; Cheok M; Celli-Lebras K; Guerin E; Terré C; Lambert J; Pautas C; Dombret H; Castaigne S; Preudhomme C; Boissel N
    Blood; 2020 Feb; 135(8):542-546. PubMed ID: 31880804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
    Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
    Hosono N; Ookura M; Araie H; Morita M; Itoh K; Matsuda Y; Yamauchi T
    Int J Hematol; 2021 Mar; 113(3):362-369. PubMed ID: 33219461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
    Hibma J; Knight B
    Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
    Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
    J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving use of gemtuzumab ozogamicin in acute myeloid leukemia.
    Walter RB
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):152-154. PubMed ID: 33739963
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.
    Khan N; Hills RK; Virgo P; Couzens S; Clark N; Gilkes A; Richardson P; Knapper S; Grimwade D; Russell NH; Burnett AK; Freeman SD
    Leukemia; 2017 May; 31(5):1059-1068. PubMed ID: 27795558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
    Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
    Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Evidence that
    Castaño-Bonilla T; Barragán E; Sargas C; Sanz A; Algarra L; Herrera-Puente P; García-Boyero R; Barrios M; Martinez-Cuadron D; Rodriguez-Veiga R; Boluda B; Gil C; Serrano-López J; Martínez-López J; Sayas-Lloris MJ; Olave MT; Riaza-Grau R; Castillo TB; Larrayoz MJ; Amigo R; Jiménez-Velasco A; Sánchez J; Ayala R; Blas C; Lainez D; Serrano-López J; Sanz MA; Alonso-Domínguez JM; Montesinos P
    Dis Markers; 2022; 2022():3132941. PubMed ID: 36051360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    Olombel G; Guerin E; Guy J; Perrot JY; Dumezy F; de Labarthe A; Bastie JN; Legrand O; Raffoux E; Plesa A; Wagner-Ballon O; Cornet E; Salaun V; Preudhomme C; Thomas X; Pautas C; Chantepie S; Turlure P; Castaigne S; Dombret H; Feuillard J
    Blood; 2016 Apr; 127(17):2157-60. PubMed ID: 26929274
    [No Abstract]   [Full Text] [Related]  

  • 19. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Gbadamosi MO; Shastri VM; Elsayed AH; Ries R; Olabige O; Nguyen NHK; De Jesus A; Wang YC; Dang A; Hirsch BA; Alonzo TA; Gamis A; Meshinchi S; Lamba JK
    Leukemia; 2022 Aug; 36(8):2022-2031. PubMed ID: 35688939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.